Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. - Wikidata - wikimedia - TriplyDB

Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.

Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.

http://www.wikidata.org/entity/Q34193317

about

Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation Effects of Adoptive Transfer of Tolerogenic Dendritic Cells on Allograft Survival in Organ Transplantation Models: An Overview of Systematic Reviews Dendritic Cells in Systemic Lupus Erythematosus: From Pathogenic Players to Therapeutic Tools Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms High-risk corneal allografts: A therapeutic challenge Metabolism Is Central to Tolerogenic Dendritic Cell Function Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity Regulatory dendritic cells for immunotherapy in immunologic diseases Dendritic cell subsets in type 1 diabetes: friend or foe?Regulatory myeloid cells in transplantation Regulatory dendritic cell therapy: from rodents to clinical application Targeting dendritic cell function during systemic autoimmunity to restore tolerance Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes Restoring immune tolerance in neuromyelitis optica: Part I Cellular Therapies in Systemic Sclerosis: Recent Progress Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus Toward beta cell replacement for diabetes Metabolic control of dendritic cell activation and function: recent advances and clinical implications Adoptive infusion of tolerogenic dendritic cells prolongs the survival of pancreatic islet allografts: a systematic review of 13 mouse and rat studies Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.Continuous retinoic acid induces the differentiation of mature regulatory monocytes but fails to induce regulatory dendritic cells Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?Orchestration of transplantation tolerance by regulatory dendritic cell therapy or in-situ targeting of dendritic cells.The role of dendritic cells in tissue-specific autoimmunity.Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential.In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies.Impaired dendritic cell function in a spontaneous autoimmune polyneuropathy.Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice.A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice.Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation.

P2860

Q21131223-FBCE2A94-2870-4657-A26E-9CAAC0450337 Q21284774-0C166578-854C-4112-8B2E-C3A35CA11DA1 Q26739998-832CF01B-B2E6-4B78-B34B-5218C29000C6 Q26749296-9F1ED279-2747-4001-B8B1-7575D9B46CC3 Q26751022-3705E968-0C60-4635-8386-073349E0D02B Q26751483-F9863397-7B27-4BB4-BE95-ED045F9160EB Q26765348-EE5C38FF-E784-42A8-A630-85867E8F4D6A Q26767458-31DECAFC-7777-43C2-808E-949063EEAB74 Q26773299-0DD7711B-E454-44DD-A30E-AD00FDF7F379 Q26776126-FD5EB291-A8E2-4094-8724-4CA43D6229FD Q26779413-0121C324-8C0B-499B-987F-7FD70C540A7D Q26781243-05A90824-CBC9-4DBF-8620-78A771F03322 Q26866216-726FBFBE-32B3-46F1-B7E0-7AF3D2CDF5B6 Q26866500-5E8EBE07-2E1A-481C-A945-A06E5E67663A Q26999875-1AD35731-07F5-4B47-8B6D-FADAD1A5792A Q27025996-6C2C1580-F2BF-42B3-8069-B23FBB56758D Q27687098-F163F7D4-D03F-470C-A110-D9627B59F679 Q28071490-675BF480-DE59-4994-A4F1-A514F730904A Q28072382-DECE590B-32E8-42A7-A23A-154407BE4C40 Q28080323-58163D1E-F408-48D5-B432-1AE272C98C64 Q28080920-2FD2DB61-77E5-421F-B3ED-92BD282CFFCD Q28083650-F5A4E576-9EFE-4B20-936E-1451C2074335 Q28385947-DDB38E2D-2337-4C01-9B77-3101FF6FCFD7 Q28484410-D83C66E3-100F-4AA3-8B13-A6426A818047 Q28596281-ADE6D3B0-7530-4835-A155-E55ACEA4F13A Q30317628-F9F24088-4D22-4237-AF00-862646A10295 Q30860263-15AEAF08-22EE-4A70-A9CC-AF0A414AC444 Q33592420-C9FC5757-96C8-4762-80EA-78A0281456FF Q34338355-DA6FC05C-8D02-4767-B41D-B4270775BF23 Q34379951-BBC28F76-A8B9-4D58-A6A8-07E3A1EF763B Q34422017-37BB3487-1EE9-4196-8E4D-D97D10278C92 Q34540737-B6180B50-1D71-4C9D-AFE2-790629F2613C Q34550631-1F3FA570-12CB-45A4-B2E3-ABF63017DF44 Q35184210-CAD2B326-60D5-4AA3-9518-F6601D9009E3 Q35472467-8DA7967E-7E3C-498E-9994-D7549FB4B204 Q35571114-0949026D-CD11-4AAA-9AFD-5F6DE5EC590D Q35843248-E3F57025-4B01-4513-B8FF-A24CBABB7798 Q36011349-9CA6AA31-6CE3-44FB-ABC4-DC7CAD5E68A5 Q36014986-CC11A2C9-5295-4839-AB91-621D79D36D7A Q36238593-B9280A93-6B99-43C2-98B0-0D05AF8A1949

P2860

Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.

http://www.wikidata.org/entity/Q34193317

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase I (safety) study of auto ...... s in type 1 diabetic patients.

@ast

Phase I (safety) study of auto ...... s in type 1 diabetic patients.

@en

Phase I

@nl

type

label

Phase I (safety) study of auto ...... s in type 1 diabetic patients.

@ast

Phase I (safety) study of auto ...... s in type 1 diabetic patients.

@en

Phase I

@nl

prefLabel

Phase I (safety) study of auto ...... s in type 1 diabetic patients.

@ast

Phase I (safety) study of auto ...... s in type 1 diabetic patients.

@en

Phase I

@nl

P1433

Q34193317-5D571785-16CE-4F3A-9C91-B4BE29FDCE18

P1476

Q34193317-B091CBCE-AC1D-4604-89E3-FD3DC409A4A4

P2093

Q34193317-255F816A-A154-4B05-B239-50DC9BD4B86F

Q34193317-45E89207-6C09-4057-B78B-2F8D6E1304E4

Q34193317-90C884B7-B910-45A1-BCA8-E951F0C83613

Q34193317-F6AE93B6-E616-4ABB-A752-B024886D37CE

P2860

Q34193317-036AFB06-EE49-4187-A336-A635EFE516F8

Q34193317-149F1373-3F30-498A-901E-ADCA6F02A1E7

Q34193317-15DF0871-66BC-4F68-B7F2-F162F1D4FCCA

Q34193317-1BC43A07-9972-4D0C-8FFB-BBC47E28C771

Q34193317-21937776-BD03-4EF5-B2C9-59D12601C9B8

Q34193317-222C5683-CD87-4CCE-B3D2-22F38D340840

Q34193317-2E52E213-EBB6-4A39-A72B-D8784B38F376

Q34193317-444B91E6-C926-43B4-B0FA-C29EB091F96B

Q34193317-54743DBA-50B4-4201-B0B2-11016CF294A7

Q34193317-5828C2D7-B606-4869-A08D-D1BF03F5C9E2

P304

Q34193317-D66EC17F-DAAE-4F81-B2AC-7CC5C7242FAA

P31

Q34193317-DAF931F0-CA6A-4118-BFB8-5AF3E69C79A3

P356

Q34193317-519F540D-B147-4401-A22D-BA7191A884B1

P407

Q34193317-572E90CF-9C07-4A7B-B8FB-02EF55C13158

P433

Q34193317-05FCE7A9-AB78-4E22-9EC5-14CBA4B3428A

P478

Q34193317-87C7C7C4-5DFF-4230-A4AF-6A8007904C78

P50

Q34193317-7DF28255-1F5B-4D21-9016-FF66C587A08B

P577

Q34193317-5A2A116E-3ED9-4CF9-918E-4763642C7464

P5875

Q34193317-4794A6CE-1136-4CD0-BF54-F11DF06DD61D

P698

Q34193317-6B54985A-4358-4EC1-8B7E-C8AFF417225B

P932

Q34193317-2EEE5DC6-2A72-4046-A4D3-DE4E863AD3B7

P356

P1433

P1476

Phase I (safety) study of auto ...... ls in type 1 diabetic patients

@en

P2093

Brett Phillips

http://www.w3.org/2001/XMLSchema#string

Jo Harnaha

http://www.w3.org/2001/XMLSchema#string

Massimo Trucco

http://www.w3.org/2001/XMLSchema#string

Nick Giannoukakis

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and Classification of Diabetes Mellitus

Standards of medical care in diabetes--2010.

CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells.

Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

Thymus-specific deletion of insulin induces autoimmune diabetes.

A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer.

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.

Regulatory dendritic cell therapy in organ transplantation.

P304

2026-2032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-0472

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

David N. Finegold

P577

2011-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51226305

http://www.w3.org/2001/XMLSchema#string

P698

21680720

http://www.w3.org/2001/XMLSchema#string

P932

3161299

http://www.w3.org/2001/XMLSchema#string